Vivlipeg

Vivlipeg (Pegfilgrastim) is a biosimilar medication used to support white blood cell production during chemotherapy. It is administered as a subcutaneous injection to reduce infection risk in cancer patients. This EU-manufactured treatment is designed for broad compatibility with chemotherapy regimens. Short-term use helps maintain immune function during treatment.

Pegfilgrastim is primarily used to reduce the duration of severe neutropenia in patients receiving chemotherapy for cancer. It stimulates the bone marrow to produce more white blood cells, helping the body fight infections. This medication is often prescribed to support patients undergoing treatments that suppress the immune system. It is not a cure for cancer but helps manage side effects of chemotherapy.

After administration, Pegfilgrastim works gradually to increase white blood cell counts over several days. Patients may notice improved energy levels as their immune system stabilizes. Some individuals report mild discomfort at the injection site following subcutaneous use. Effects vary based on individual response and chemotherapy schedules.

Keep Vivlipegim refrigerated until use to maintain potency. Avoid shaking the vial or prefilled syringe to prevent damage to the medication. Discard any unused portion after the prescribed dose. Always follow healthcare provider instructions for proper disposal of needles and syringes. Inform your doctor of any allergies before starting treatment.

Pegfilgrastim may interact with other medications that affect bone marrow function, such as certain chemotherapy drugs. Combining it with lithium can increase the risk of excessive white blood cell production. No major food interactions are known, but alcohol may reduce effectiveness. Always disclose all medications to your healthcare provider before starting Pegfilgrastim.